Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for MRKR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 -9.756M
March 31, 2026 -7.918M
December 31, 2025 -12.01M
September 30, 2025 -14.82M
June 30, 2025 -10.88M
March 31, 2025 -12.57M
December 31, 2024 -10.91M
September 30, 2024 -8.575M
June 30, 2024 -10.90M
March 31, 2024 -14.39M
December 31, 2023 -16.44M
September 30, 2023 -20.38M
June 30, 2023 -26.90M
March 31, 2023 -20.63M
December 31, 2022 -26.97M
September 30, 2022 -25.52M
June 30, 2022 -24.39M
March 31, 2022 -30.51M
December 31, 2021 -27.28M
September 30, 2021 -28.64M
June 30, 2021 -26.36M
March 31, 2021 -23.81M
December 31, 2020 -18.86M
September 30, 2020 -17.20M
June 30, 2020 -18.63M
Date Value
March 31, 2020 -18.45M
December 31, 2019 -18.28M
September 30, 2019 -19.89M
June 30, 2019 -17.79M
March 31, 2019 -16.01M
December 31, 2018 -14.48M
September 30, 2018 -10.80M
June 30, 2018 -9.249M
March 31, 2018 -8.862M
December 31, 2017 -8.439M
September 30, 2017 -7.715M
June 30, 2017 -7.662M
March 31, 2017 -7.604M
December 31, 2016 -6.510M
September 30, 2016 -5.607M
June 30, 2016 -5.300M
March 31, 2016 -4.159M
December 31, 2015 -4.343M
September 30, 2015 -4.162M
June 30, 2015 -3.403M
March 31, 2015 -2.828M
December 31, 2014 -2.187M
September 30, 2014 -1.534M
June 30, 2014 -0.7628M
March 31, 2014 -0.6731M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Krystal Biotech, Inc. 272.34M
Ironwood Pharmaceuticals, Inc. 185.56M
SELLAS Life Sciences Group, Inc. -28.42M
Rezolute, Inc. -73.48M
ADMA Biologics, Inc. 136.72M